Today, we are looking back a conversation I had last year with Howard Berman, co-founder and CEO of Coya Therapeutics, which has had quite the busy summer. The company expanded its collaboration with Houston Methodist Research Institute and started looking into how GLP-1 drugs can enhance the effects of its proprietary therapeutics.
Read more about these two news stories from this summer on InnovationMap:
